Active	Status	Sponsor type	Region	Phase	Filter
4 Active 3 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
DA8010 / Dong-A
NCT05282069: A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder	Completed	3	607	RoW	DA-8010 Placebo, DA-8010 2.5mg, DA-8010 5mg, Solifenacin 5mg, Solifenacin succinate placebo	Dong-A ST Co., Ltd.	Overactive Bladder	11/23	05/24
NCT05992428: Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults	Completed	1	37	RoW	DA-8010 5mg, Paroxetine 20mg, Mirabegron 50mg	Dong-A ST Co., Ltd.	Healthy	11/23	12/23
NCT05991401: Evaluate the Effect of Clarithromycin/Rifampicin on the Pharmacokinetics of DA-8010 in Healthy Adults	Completed	1	18	RoW	DA-8010 5mg, Clarithromycin 500mg, Rifampicin 600mg	Dong-A ST Co., Ltd.	Healthy	11/23	11/23
NCT05812417: A Study to Evaluate the Effects of Renal Function on Pharmacokinetics and Safety of DA-8010	Completed	1	33	RoW	DA-8010	Dong-A ST Co., Ltd.	Renal Impairment, Healthy	06/24	06/24